Skip to main content

Chronic Cough clinical trials at UC Davis
1 research study open to eligible people

  • A Study of Experimental Inhaled RVT-1601 for Idiopathic Pulmonary Fibrosis (IPF)

    open to eligible people ages 40-89

    Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is characterized by exertional dyspnea and persistent dry cough. Cough in IPF is both a presenting and a complicating clinical feature, which affects approximately three quarters of IPF cases. It is often a debilitating symptom that adversely affects quality of life (QoL) and is usually refractory to medical therapy. Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b study for the treatment of persistent cough in patients with IPF.

    Sacramento, California and other locations

Last updated: